Compare Bristol-Myers Squibb Co (BMY) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Boston Beer Company Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.3 (market cap $116.30B), while Boston Beer Company Inc trades at $173.31 (market cap $1.76B). The key difference: Bristol-Myers Squibb Co is far larger — about 66.1× Boston Beer Company Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| BMY | SAM | |
|---|---|---|
Market Cap | $116.30B | $1.76B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $260.05 |
52-Week Low | $42.60 | $161.08 |
Enterprise Value | $152.24B | $1.63B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Boston Beer Company (SAM) trades at $172.39, down 2.49% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, but faces headwinds with negative 2026 profit margin projections. Recent news highlights innovation in Beyond Beer products and marketing initiatives, though Q1 2026 earnings missed expectations and volume growth concerns persist.
The stock presents a cautious opportunity with analyst consensus target of $213.50 offering 24% upside, but investors face risks from declining volumes, margin pressure, and competitive threats. While cash flow remains positive and valuation ratios appear reasonable, the negative 2026 earnings outlook and bearish technical momentum warrant careful monitoring of upcoming Q2 results and brand performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
